Vaxcyte Return On Equity from 2010 to 2025

PCVX Stock  USD 71.90  1.92  2.60%   
Vaxcyte Return On Equity yearly trend continues to be fairly stable with very little volatility. Return On Equity will likely drop to -0.15 in 2025. Return On Equity is a measure of the profitability of Vaxcyte in relation to the equity, calculated by dividing net income by shareholder's equity. View All Fundamentals
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(0.14)
Current Value
(0.15)
Quarterly Volatility
0.35460259
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 115.5 M, Interest Expense of 0.0 or Selling General Administrative of 97.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Return On Equity Growth Pattern

Below is the plot of the Return On Equity of Vaxcyte over the last few years. Return on Equity is the amount of Vaxcyte net income returned as a percentage of Vaxcyte equity. Return on equity measures Vaxcyte profitability by revealing how much profit Vaxcyte generates with the money shareholders have invested. It is a measure of the profitability of a business in relation to the equity, calculated by dividing net income by shareholder's equity. Vaxcyte's Return On Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported -0.210 Years Trend
Slightly volatile
   Return On Equity   
       Timeline  

Vaxcyte Return On Equity Regression Statistics

Arithmetic Mean(0.31)
Geometric Mean0.40
Coefficient Of Variation(115.41)
Mean Deviation0.26
Median(0.35)
Standard Deviation0.35
Sample Variance0.13
Range1.0679
R-Value0.47
Mean Square Error0.10
R-Squared0.23
Significance0.06
Slope0.04
Total Sum of Squares1.89

Vaxcyte Return On Equity History

2025 -0.15
2024 -0.14
2023 -0.32
2021 -0.35
2020 -0.25
2019 0.5
2018 0.51

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Return On Equity, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Equity(0.14)(0.15)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.